PrøvGOLD- Free

European agency endorses approval of Biocon Biologics' biosimilar Ustekinumab
The New Indian Express Anantapur|December 17, 2024
BIOCON BIOLOGICS, a biosimilars company and subsidiary of Biocon, has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of YESINTEK, an Ustekinumab biosimilar intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease.
- ENS ECONOMIC BUREAU @ Bengaluru

It said clinical studies showed the Ustekinumab biosimilar has a similar pharmacokinetic, safety, efficacy and immunogenicity profile compared with the originator product.

Denne historien er fra December 17, 2024-utgaven av The New Indian Express Anantapur.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

European agency endorses approval of Biocon Biologics' biosimilar Ustekinumab
Gold Icon

Denne historien er fra December 17, 2024-utgaven av The New Indian Express Anantapur.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA THE NEW INDIAN EXPRESS ANANTAPURSe alt
The New Indian Express Anantapur

Paid subscriptions soar, but still OpenAI loses money!

OpenAI CEO Sam Altman recently shared a surprising admission on X (formerly Twitter) about the company's financial difficulties surrounding ChatGPT Pro subscriptions.

time-read
2 mins  |
January 10, 2025
The New Indian Express Anantapur

Paid subscriptions soar, but still OpenAI loses money!

pricing for Pro subscriptions is now facing scrutiny as the company grapples with the unexpected rise in operational costs.

time-read
1 min  |
January 10, 2025
The New Indian Express Anantapur

India's Smartphone Market Set to Cross $50 Billion in 2025

CONSUMERS WILLING TO PAY MORE

time-read
1 min  |
January 10, 2025
The New Indian Express Anantapur

Fielding holding Shafali back from returning to side?

WITH the series against Ireland starting soon, a source close to BCCI has said that it is up to the team management and players to make the most of the chances they are given.

time-read
2 mins  |
January 10, 2025
The New Indian Express Anantapur

Boxers Shiva, Sachin shine

REIGNING champion Shiva Thapa began his title defence with a commanding win over Enayat Khan in welterweight (60-65kg) category at the 8th Elite Men's National Boxing Championship here on Thursday.

time-read
1 min  |
January 10, 2025
The New Indian Express Anantapur

ISL: Sting in tail for Chennaiyin FC in draw against Odisha

ODISHA FC scored an injury-time goal to snatch a point against Chennaiyin FC in the Indian Super League here on Thursday.

time-read
1 min  |
January 10, 2025
The New Indian Express Anantapur

Jigsaw puzzle for selectors ahead of CT

Focus shifts to England series including 5 T20Is & 3 ODIs with latter taking prominence thanks to proximity of ICC event

time-read
1 min  |
January 10, 2025
The New Indian Express Anantapur

Defending champ Sinner opens against Jarry

JANNIK Sinner was drawn on Thursday against big-hitting Nicolas Jarry to start his Australian Open defence while Novak Djokovic is on a collision course to meet Carlos Alcaraz in the quarter-finals.

time-read
1 min  |
January 10, 2025
The New Indian Express Anantapur

Vijay Hazare Trophy: Tomar helps Rajasthan beat TN in pre-quarters

OPENER Abhijeet Tomar struck a well-paced hundred as Rajasthan recorded their first ever win over Tamil Nadu in Vijay Hazare Trophy history to enter the quarterfinals here on Thursday.

time-read
1 min  |
January 10, 2025
The New Indian Express Anantapur

Spurs Beat Liverpool in League Cup Semifinal

LIVERPOOL boss Arne Slot slammed the controversial decision not to send off Tottenham's Lucas Bergvall before the teenager sealed a 1-0 win in the League Cup semi-final first leg on Wednesday.

time-read
1 min  |
January 10, 2025

Vi bruker informasjonskapsler for å tilby og forbedre tjenestene våre. Ved å bruke nettstedet vårt samtykker du til informasjonskapsler. Finn ut mer